CSF1R and colorectal carcinoma: The utility of CSF1R inhibitors and ICIs in CRC, a tumor-type in which CSF1R-positive TAMs predominate and mediate an immunosuppressive tumor milieu [30], is currently under investigation in multiple early-phase studies (i.e., NCT02777710, NCT02452424, NCT02829723, NCT02880371).